Wedbush Has Negative Outlook for Immunome Q3 Earnings

Key Points

• Wedbush analysts downgraded their Q3 2025 earnings estimates for Immunome, predicting an earnings per share of ($0.50), down from a previous estimate of ($0.45).
• Immunome reported revenue of $4.02 million for the latest quarter, significantly exceeding the consensus estimate of $1.03 million.
• As of now, Immunome holds a market capitalization of $843.42 million, with shares currently trading around $9.69.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at Wedbush reduced their Q3 2025 EPS estimates for shares of Immunome in a research report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.50) per share for the quarter, down from their previous forecast of ($0.45). Wedbush currently has a "Outperform" rating and a $21.00 target price on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome's Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.04) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($0.21) EPS.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.02. The company had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%.

Several other research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. lowered their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $23.14.

Immunome Stock Up 0.9%

Shares of IMNM stock traded up $0.09 on Monday, reaching $10.10. The stock had a trading volume of 142,437 shares, compared to its average volume of 1,014,330. The firm's 50-day moving average is $9.59 and its two-hundred day moving average is $8.91. The firm has a market capitalization of $879.10 million, a price-to-earnings ratio of -3.28 and a beta of 1.93. Immunome has a 12 month low of $5.15 and a 12 month high of $16.73.

Insider Transactions at Immunome

In related news, Director Jean Jacques Bienaime bought 5,000 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were purchased at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the completion of the transaction, the director directly owned 36,415 shares of the company's stock, valued at approximately $341,572.70. This represents a 15.92% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 7.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On Immunome

A number of hedge funds have recently modified their holdings of the business. Enavate Sciences GP LLC acquired a new position in Immunome in the fourth quarter valued at $36,939,000. Primecap Management Co. CA raised its holdings in shares of Immunome by 1,115.7% during the first quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company's stock valued at $22,974,000 after purchasing an additional 3,132,900 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock valued at $50,843,000 after purchasing an additional 2,054,640 shares during the period. Vanguard Group Inc. raised its holdings in shares of Immunome by 43.4% during the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company's stock valued at $28,987,000 after purchasing an additional 1,303,753 shares during the period. Finally, Woodline Partners LP raised its holdings in shares of Immunome by 69.0% during the first quarter. Woodline Partners LP now owns 1,657,729 shares of the company's stock valued at $11,157,000 after purchasing an additional 676,804 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.